摘要:
The present invention provides a Piper laetispicum extract, the preparation method therefor and the use thereof. The Piper laetispicum extract includes: sesamin; (2E,6E) -N-isobutyl-7- (3,4-methylenedioxyphenyl) heptadienamide; (2E, 4E) -N-isobutyldodecane-2,4-dieneamide; (2E, 4E) -N-isobutyl-15-phenylpentadeca-2,4-dieneamide; (2E, 4E, 14Z) -N-isobutyleicosane-2,4,14-trienamide; and (2E, 4E) -N-isobutyl-13-phenyltrideca-2,4-dieneamide. The Piper laetispicum extract can prevent depression.
摘要:
The present invention provides a method for producing a disulfonylamine alkali metal salt, including a step of subjecting a disulfonylamine onium salt represented by formula [I] (wherein each of R 1 and R 2 independently represents a fluorine atom or a fluorinated alkyl group having 1 to 6 carbon atoms, provided that at least one of R 1 and R 2 represents a fluorine atom, and each of R 3 , R 4 , R 5 and R 6 independently represents a hydrogen atom or the like) to a cation exchange reaction in an organic solvent, thereby producing a disulfonylamine alkali metal salt represented by formula [II] (wherein M + represents an alkali metal cation, and R 1 and R 2 are as defined in formula [I]), and a step of filtering the organic solvent solution containing the disulfonylamine alkali metal salt through a filter having a particle retention size of 0.1 to 10 µm to obtain a filtrate.
摘要:
The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below (M)-L-(M') (I), wherein M and M', the same or different from each other, represent the residues of the metalloproteases inhibitors of formula (II), wherein R, R 1 , R 2, R 3 , G and n have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.
摘要:
(R) and (S) 2-Aryl-propionic acids, and pharmaceutical compositions that contain them, are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The acids are used for the prevention and treatment of pathologies deriving from said activation. In particular, the (R) enantiomers of said acids are lacking cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.